Clinical trials: Circulating Tumor Cell, open to volunteers
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Brain Tumor, Primary, Brain Tumor - Metastatic
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the…
- Trial name
- NCT05831631
- Testing
- Circulating leukocytes immunophenotype, Tumor sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Pietro Mortini, MD, Prof.
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace
Triple Negative Breast Cancer
MicroRNA Profiles in Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups.
- Trial name
- TARMAC (NCT04771871)
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 42 people
- Sponsor
- University College Hospital, Ibadan
Cancer, Immune System or Toxicities Suspected
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
- Trial name
- ALCYTA (NCT05354765)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Breast Neoplasms, Neoplastic Cells, Circulating
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without…
- Conditions
- Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect
- Trial name
- NCT05326295
- Testing
- CTC detection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hunan Cancer Hospital
Urothelial Carcinoma
Liquid Biospy for Urinary Cancers
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and…
- Trial name
- CIRCE (NCT06116396)
- Testing
- Genetic analysis on isolated cells
- Where
- Italy
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-small Cell Lung Cancer
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and…
- Trial name
- NCT06358222
- Testing
- Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA, Intraoperative lymph node dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma.
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT04564989
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Biomarkers for Risk Stratification in Lung Cancer
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco…
- Trial name
- NCT03774758
- Testing
- Guardant Health ct-DNA LUNAR assay
- Where
- 3 sites in United States
- Volunteers
- 1,440 people
- Sponsor
- University of California, San Francisco
Rectal Cancer Patients
Rectal Cancer CTC Trial
This prospective, multi-centre, randomised clinical trial aims to compare the effect of neoadjuvant chemoradiotherapy versus primary surgery on circulating tumor cells (CTCs) in patients with stage II-III rectal cancer without…
- Trial name
- NCT07194616
- Testing
- Primary Surgery, Neoadjuvant radiochemotherapy and surgery
- Where
- 4 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- University Hospital Ostrava
Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck…
- Conditions
- Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
- Trial name
- NCT06915038
- Testing
- NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indiana University
Locally Advanced Head and Neck Carcinoma
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
- Trial name
- NeckTAR-IN (NCT07178847)
- Testing
- blood sampling
- Where
- 4 sites in France
- Volunteers
- 59 people
- Sponsor
- Centre Jean Perrin
Objective Responsive Rate (ORR)
Dynamic Changes in Circulating Tumour Cells Protein Expression
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at…
- Trial name
- Liquid-DRER2 (NCT06314997)
- Testing
- panitumumab (EGFR inhibitors)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Matteo's Friends
Circulating Tumor Cell, Nasopharyngeal Carcinoma
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting…
- Conditions
- Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
- Trial name
- NCT04544969
- Testing
- cisplatin-based chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Neuroendocrine Tumors, MEN1 Mutation
Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation
Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disease with a high degree of penetrance (>80% of patients). It is caused by the presence of the MEN1 mutation located on chromosome 11q13.
- Trial name
- PRO-NEM1 (NCT06430021)
- Testing
- blood sample
- Where
- France
- Volunteers
- 297 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different…
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06678724
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital